Euclidean Capital LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Euclidean Capital LLC reported 10 stock positions worth $439.8 million. Its top holding was Vanguard Ftse All-World Ex-U (VEU) at 61.8% of the portfolio, followed by Vanguard Mrngstr Val ETF-Aui (VTV, 25.8%) and iShares MSCI India ETF (INDA, 4.2%). Compared with Q1 2026, it opened 1 new position. The biggest buy was a new position in Teamshares (TMS).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001825034
- Portfolio Value
- $439.8M (Q2 2026)
- SEC Filing
- 0001012975-26-000776 ↗ filed Aug 14, 2026
Holdings Value
Holdings 10 stocks · $439.8M
| VEU Vanguard Ftse All-World Ex-U | 61.76% | 3,243,484 | $271.6M | No change |
| VTV Vanguard Mrngstr Val ETF-Aui | 25.77% | 520,000 | $113.3M | No change |
| INDA iShares MSCI India ETF | 4.15% | 369,600 | $18.3M | No change |
| ORIC Oric Pharmaceuticals Inc. | 2.44% | 989,410 | $10.7M | No change |
| TMS Teamshares Inc. | 2.06% | 1,099,974 | $9.0M | New |
| FHTX Foghorn Therapeutics Inc. | 1.75% | 1,573,761 | $7.7M | No change |
| PMVP PMV Pharmaceuticals Inc. | 0.80% | 2,627,643 | $3.5M | No change |
| ALEC Alector Inc. | 0.60% | 1,307,858 | $2.6M | No change |
| SRZN Surrozen Inc. | 0.52% | 87,696 | $2.3M | No change |
| TNYA Tenaya Therapeutics Inc. | 0.17% | 1,015,705 | $751K | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $3K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| SRZNW Surrozen Inc.-CW25 | *W EXP 08/01/203 | 170,833 | $3K | No change |
Total filed on the 13F, all lines: $439.8M.
Portfolio Sells Q1 2026 → Q2 2026
| None this quarter. | |||
Portfolio Buys Q1 2026 → Q2 2026
| TMS Teamshares Inc. | New | 2.06% | +2.06 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $439.8M | VEU, VTV, INDA, ORIC, TMS |
| Q1 2026 | 9 | $392.3M | VEU, VTV, INDA, ORIC, FHTX |
| Q4 2025 | 11 | $369.4M | VEU, VTV, INDA, FHTX, ORIC |
| Q3 2025 | 10 | $238.0M | VEU, INDA, ORIC, FHTX, ALEC |
| Q2 2025 | 10 | $305.7M | VEU, INDA, ORIC, FHTX, PMVP |
| Q1 2025 | 10 | $266.1M | INDA, VEU, FHTX, ORIC, PMVP |
| Q4 2024 | 10 | $736.7M | SPY, INDA, VEU, ORIC, FHTX |
| Q3 2024 | 11 | $906.8M | SPY, INDA, VEU, FHTX, ORIC |
| Q2 2024 | 10 | $795.8M | SPY, INDA, FHTX, ORIC, ALEC |
| Q1 2024 | 12 | $780.0M | SPY, INDA, GLD, ORIC, FHTX |